Both stents are designed to treat coronary artery disease.
Abbott claims that its just-approved everolimus-eluting stent, XIENCE V, has demonstrated superiority over Boston Scientifics paclitaxel-eluting stent TAXUS based on two randomized head-to-head clinical trials. But Boston Scientific executives aren't worried. That's because the Natick, Mass., firm is also launching an everolimus-eluting stent, called PROMUS. In fact, PROMUS is a private-label form of XIENCE V and, as such, the two are identical. Boston Scientific is able to distribute PROMUS thanks to a deal it signed prior to its 2006 acquisition of the former Guidant Corp. Both XIENCE V and PROMUS are designed to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the anti-rejection drug everolimus in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. Industry experts have forecasted that stent prices will come down thanks to the introduction of these competing products.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.